Quality of Life Findings from NETTER-1 Phase III Study at ENETS

aaa logo

AAA announced that quality of life findings from the pivotal NETTER-1 Phase III study investigating the treatment of Lutetium Lu 177 Dotatate in patients with somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) was presented at the 14th Annual Conference of the European Neuroendocrine Tumor Society (ENETS), March 8-10 in Barcelona, Spain.

The details of the presentations are as follows:
Abstract # 1676: NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumours
Session Date: March 9, 2017

To read more please visit the AAA website…  or read the full press release here

Join our NET Community

Sign-up for our email newsletter. Simply register with us to receive regular updates.

Register now